Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Morie Gertz
Mayo Clinic, Rochester, Minnesota, USA
Morie Gertz, MD, is the Roland Seidler Jr. Professor of the Art of Medicine, and Chair Emeritus of the Department of Internal Medicine, at the Mayo Clinic in Rochester, Minnesota, USA. read more
Prof. Gertz has served as chair of the Division of Haematology and chair of the Department of Medicine at the Mayo Clinic in Rochester. He was the first treasurer of the International Society of Amyloidosis, and the International Myeloma Society.Â
Prof. Gertz has authored over 1,000 peer reviewed publications and over 90 book chapters. He serves on the editorial boards of Amyloidosis, Acta Haematologica and Clinical Lymphoma & Myeloma. He is co-editor of Neoplastic Diseases of the Blood. In 2019, the Department of Medicine awarded him its lifetime research achievement award. In 2021, he was appointed chair of the committee for the hematology certification examination for the American Board of Internal Medicine.
Prof. Morie Gertz discloses: Advisory board/panel fees from AbbVie, Aptitude, Ashfield, Celgene, Ionis/Akcea, Janssen, Johnson & Johnson, Prothena, Sanofi and Sorrento. Grants/research support from: Ashfield and Juno.
Prof. Bernd Jilma
Medical University of Vienna, Vienna, Austria
Bernd Jilma, MD, holds a tenure position as Professor for Internal Medicine and Clinical Pharmacology at the Medical University of Vienna, Austria. read more
For almost 30 years, Prof. Jilma has worked in the field of clinical pharmacology. He has served on various regulatory committees of the European Medicines Agency and was the Austrian delegate and member of the Committees of Orphan Medicinal Products (COMP), the Scientific Advice Working Party (SAWP), and the Committee for Advanced Therapies (CAT).Â
His early research career focused on evaluating anticoagulants in endotoxemia-driven coagulation. Prof. Jilma identified potentially detrimental drug interactions of morphine and platelet function inhibitors. Early clinical phase I/II trials with an aptamer directed against von Willebrand factor provided proof of concept for the treatment of thrombotic thrombocytopenic purpura. This encouraged further development of a biologic (nanobody) directed against the same target, which eventually led to the marketing approval of caplacizumab. Prof. Jilma also designed the phase I–III trials which led to marketing authorization of the C1s complement inhibitor sutimlimab for the treatment of cold agglutinin disease.Â
Prof. Jilma has authored more than 500 papers in peer-reviewed international journals including New England Journal of Medicine, Lancet and Blood.
Prof. Bernd Jilma discloses: Advisory board/panel and speaker’s bureau fees from Sanofi.
Dr Shirley D'Sa
University College London Hospitals, London, UK
Shirley D’Sa, MD, FRCP, FRCPath, is a haematologist and Associate Professor at University College London Hospitals (UCLH) NHS Foundation Trust in London, UK, where she also completed her specialist training in haematology. read more
Dr D’Sa specialises in the management of patients with IgM-related conditions and paraproteinaemic neuropathies.
She is clinical lead for the UCLH Centre for Waldenström’s macroglobulinemia (WM) and Related Disorders, and haematological lead in the Joint Neurohaematology Service alongside the neurology lead, Prof. Michael Lunn at the National Hospital for Neurology, Queen Square, in London.
Dr D’Sa is a chief/principal investigator in several clinical trials in Waldenstrӧm’s macroglobulinemia (WM) and cold agglutinin disease (CAD) and is a committee member on the International Workshop on WM, and the British Society for Haematology Guidelines Group.
Dr D’Sa is a co-trustee with patients and colleagues in the UK Registered Charity, WMUK and the chief investigator for the Rory Morrison WMUK Registry project and associated conditions, which has more than 1,100 patients registered from several centres across the UK. She is also a member of the Medical Advisory Panel of Lymphoma Action in the UK.
Dr Shirley D’Sa discloses: Advisory board/panel fees from BeiGene, Janssen and Sanofi. Consultancy fees from BeiGene and Sanofi. Grants/research support and speaker’s bureau fees from BeiGene.
